Froedtert Health was among the investors in Xealth, a digital prescribing platform that raised $11 million in Series A funding.
The Froedtert and the Medical College network also has been using the Xealth platform for over 13 months in combination with products from Proteus Digital Health.
A small wearable patch from Proteus Health helps monitor patient use of the company’s digital medicines. An app captures that information and more data for patients and their physicians.
Xealth, of Seattle, links data from Proteus to patients’ electronic health records. Patients are able to share data about their experience with digital medications with their health care clinicians.
Froedtert Health, through its Inception Health subsidiary, invested in Xealth previously as well as investing in the latest round.
“Our investment in Xealth reflects the Froedtert and the Medical College of Wisconsin health network’s belief that digital technology and therapeutics are highly impactful in improving the health of our patients,” said Inception Health president Mike Anderes. “Xealth gives us the power to bring those tools to our community with great efficiency and precision.”
Wauwatosa-based Froedtert Health in 2018 launched a $15 million health-tech investment fund. Inception Health, which has its offices in Menomonee Falls, has invested about $45 million since 2015. The company invests directly in startups and also in Avia of Chicago, which vets and “de-risks” investment prospects.
Xealth said the existing investors in the Series A financing round besides Froedtert were Threshold Ventures (formerly DFJ Venture), Providence Ventures and UPMC. New investors in Xealth were McKesson Ventures, Novartis, Philips and ResMed. Read the full story here.